Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 7Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Lung Neoplasms 2Hematologic Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma 1Liver Neoplasms 1Glioma 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 3Trastuzumab 2Interleukin-12 Subunit p35 2Drug Therapy 2tivozanib 1tipifarnib 1spartalizumab 1seribantumab 1pertuzumab 1motexafin lutetium 1irinotecan sucrosofate 1entinostat 1atezolizumab 1Specimen Handling 1Ritonavir 1Quality of Life 1Positron Emission Tomography Computed Tomography 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Paclitaxel 1Oxaliplatin 1Ondansetron 1Octreotide 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Mesna 1Magnetic Resonance Spectroscopy 1Leucovorin 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × pertuzumab × Gynecologic × Clear all
NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
796 enrolled
BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡